Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lizasai is a biological drug product composed of an extract from the skin of rabbits that have been inflamed by inoculation with the vaccinia virus. Developed by Weishi Pharmaceuticals (Rugao) Co., Ltd., it is currently being evaluated in Phase II clinical trials in China for the treatment of acute ischemic stroke. The extract is a complex mixture of non-protein bioactive substances that exhibit neuroprotective, anti-inflammatory, and analgesic properties. Its mechanism of action in stroke is thought to involve the reduction of oxidative stress, inhibition of inflammatory cytokines, and stabilization of neuronal membranes, thereby limiting the progression of ischemic damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaccinia virus-inflamed rabbit skin extract.